DE69729292D1 - Kurze externe führungssequenzen - Google Patents
Kurze externe führungssequenzenInfo
- Publication number
- DE69729292D1 DE69729292D1 DE69729292T DE69729292T DE69729292D1 DE 69729292 D1 DE69729292 D1 DE 69729292D1 DE 69729292 T DE69729292 T DE 69729292T DE 69729292 T DE69729292 T DE 69729292T DE 69729292 D1 DE69729292 D1 DE 69729292D1
- Authority
- DE
- Germany
- Prior art keywords
- molecules
- rnase
- segs
- target
- stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 239000000758 substrate Substances 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000006225 natural substrate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/316—Phosphonothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Saccharide Compounds (AREA)
- Pens And Brushes (AREA)
- Seal Device For Vehicle (AREA)
- Prostheses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/615,961 US5877162A (en) | 1996-03-14 | 1996-03-14 | Short external guide sequences |
US615961 | 1996-03-14 | ||
PCT/US1997/003847 WO1997033991A1 (en) | 1996-03-14 | 1997-03-14 | Short external guide sequences |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69729292D1 true DE69729292D1 (de) | 2004-07-01 |
DE69729292T2 DE69729292T2 (de) | 2005-06-02 |
Family
ID=24467475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69729292T Expired - Lifetime DE69729292T2 (de) | 1996-03-14 | 1997-03-14 | Kurze externe führungssequenzen |
Country Status (9)
Country | Link |
---|---|
US (1) | US5877162A (de) |
EP (1) | EP0894129B1 (de) |
JP (1) | JP4062365B2 (de) |
AT (1) | ATE267866T1 (de) |
AU (1) | AU2206197A (de) |
DE (1) | DE69729292T2 (de) |
DK (1) | DK0894129T3 (de) |
ES (1) | ES2221955T3 (de) |
WO (1) | WO1997033991A1 (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE321882T1 (de) | 1997-07-01 | 2006-04-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
US20030165888A1 (en) * | 2001-07-18 | 2003-09-04 | Brown Bob D. | Oligonucleotide probes and primers comprising universal bases for diagnostic purposes |
US6518017B1 (en) * | 1997-10-02 | 2003-02-11 | Oasis Biosciences Incorporated | Combinatorial antisense library |
JP2001519141A (ja) * | 1997-10-07 | 2001-10-23 | スミスクライン・ビーチャム・コーポレイション | 遺伝子発現の調節方法 |
EP1032707A2 (de) * | 1997-11-21 | 2000-09-06 | Yale University | Verfahren zur identifizierung und inhibierung funktionaler nukleinsäuremoleküle in zellen |
US6013447A (en) * | 1997-11-21 | 2000-01-11 | Innovir Laboratories, Inc. | Random intracellular method for obtaining optimally active nucleic acid molecules |
US6248525B1 (en) | 1998-03-30 | 2001-06-19 | Yale University | Method for identifying essential or functional genes |
WO1999060012A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
WO2000061810A1 (en) * | 1999-04-08 | 2000-10-19 | Oasis Biosciences, Inc. | Antisense oligonucleotides comprising universal and/or degenerate bases |
DK1860188T3 (da) | 1999-07-07 | 2011-06-27 | Zymogenetics Inc | Human cytokin-receptor |
US6677445B1 (en) | 1999-08-27 | 2004-01-13 | Chiron Corporation | Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
EP1326892A2 (de) | 2000-10-12 | 2003-07-16 | University of Rochester | Zusammensetzungen die die proliferation von krebszellen hemmen |
WO2003065997A2 (en) | 2002-02-06 | 2003-08-14 | Vicor Technologies, Inc. | Anti-infarction molecules |
AU2003253580A1 (en) * | 2002-02-26 | 2003-11-17 | University Of Minnesota | Variants of nedd4l associated with hypertension and viral budding |
CA2495478A1 (en) | 2002-08-05 | 2004-02-12 | University Of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
US9233120B2 (en) | 2002-11-15 | 2016-01-12 | Jyant Technologies | Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration |
US8512701B2 (en) | 2002-11-15 | 2013-08-20 | Morehouse School Of Medicine | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
US8658377B2 (en) | 2002-11-15 | 2014-02-25 | Morehouse School Of Medicine | Detecting cancer with anti-CCL25 and anti-CCR9 antibodies |
WO2004106488A2 (en) * | 2003-05-12 | 2004-12-09 | Potomac Pharmaceuticals, Inc. | Gene expression suppression agents |
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
BRPI0411219A (pt) * | 2003-06-12 | 2006-07-18 | Nucleonics Inc | seqüências de hbv e hcv conservadas úteis para silenciamento de gene |
WO2005021751A1 (en) * | 2003-09-01 | 2005-03-10 | Patrick Arbuthnot | A self-processing rna expression cassette |
ES2332712T3 (es) * | 2003-12-16 | 2010-02-11 | Bio-Rad Pasteur | Oligonucleotidos para la deteccion del virus de la hepatitis b. |
EP1858916B1 (de) | 2005-03-15 | 2014-07-09 | Fujirebio Europe N.V. | Hepatitis-b-virusvarianten mit verminderter empfindlichkeit gegenüber nukleosidanalogen und verwendung davon |
NZ561883A (en) | 2005-03-23 | 2010-11-26 | Genmab As | Antibodies against CD38 for treatment of multiple myeloma |
US7476733B2 (en) * | 2005-03-25 | 2009-01-13 | The United States Of America As Represented By The Department Of Health And Human Services | Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease |
EP1934244A2 (de) * | 2005-10-06 | 2008-06-25 | Emthrax LLC | Verfahren und zusammensetzungen in verbindung mit milzbrandsporen-glycoproteinen als impfstoffe |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
CA2625891A1 (en) * | 2005-10-14 | 2007-04-26 | Carlton D. Donald | Inhibition of pax2 by defb1 induction as a therapy for cancer |
CA2981308C (en) | 2006-09-21 | 2020-12-22 | University Of Rochester | Compositions and methods related to protein displacement therapy for myotonic dystrophy |
WO2008136852A2 (en) | 2006-11-01 | 2008-11-13 | University Of Rochester | Methods and compositions related to the structure and function of apobec3g |
BRPI0720038A2 (pt) | 2006-12-11 | 2013-12-24 | Univ Utah Res Found | Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor |
US20100239596A1 (en) * | 2007-08-22 | 2010-09-23 | University Of Southern California | Grp78 and tumor angiogenesis |
DK2682400T5 (da) | 2007-08-28 | 2017-11-27 | Uab Research Foundation | Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse |
JP2010537638A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法 |
US8501912B2 (en) * | 2007-12-03 | 2013-08-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Filipil compositions and methods for treating cancer |
US20090233993A1 (en) * | 2008-03-06 | 2009-09-17 | Burnham Institute For Medical Research | Compositions and methods for inhibiting gsk3 activity and uses thereof |
US20090253174A1 (en) * | 2008-04-08 | 2009-10-08 | Zach Serber | Expression of Heterologous Sequences |
EP2288922B1 (de) | 2008-05-08 | 2016-08-17 | University of Utah Research Foundation | Sensorische rezeptoren für chronische müdigkeit und schmerzen und verwendungen dafür |
US20120070443A1 (en) | 2008-12-02 | 2012-03-22 | University Of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
WO2010074924A1 (en) | 2008-12-23 | 2010-07-01 | University Of Utah Research Foundation | Identification and regulation of a novel dna demethylase system |
CN102405054A (zh) * | 2009-02-06 | 2012-04-04 | 柏林自由大学 | 用于治疗给药镜像适配体引起的不良反应的含l-核酶的药物组合物 |
CN101634047A (zh) * | 2009-08-12 | 2010-01-27 | 广州金琪基因技术研究发展中心 | 一种外指引序列文库筛选方法 |
US20110060000A1 (en) | 2009-09-10 | 2011-03-10 | Maurizio Grimaldi | Acridine analogs in the treatment of gliomas |
US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
ES2639420T3 (es) | 2010-11-10 | 2017-10-26 | Nigel L. Webb | Nucliones y ribocápsides |
JP2014505239A (ja) | 2010-12-14 | 2014-02-27 | モアハウス スクール オブ メディスン | 癌の治療または検出のための抗cxcl13および抗cxcr5抗体の使用 |
JP7081923B2 (ja) | 2014-07-31 | 2022-06-07 | ユーエイビー リサーチ ファンデーション | アポe模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果 |
US11260076B2 (en) | 2014-10-27 | 2022-03-01 | University Of Central Florida Research Foundation, Inc | Methods and compositions for natural killer cells |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
US10723794B2 (en) | 2015-03-18 | 2020-07-28 | University Of South Carolina | Anti-CcL8 antibodies and uses thereof |
CN110087665A (zh) | 2016-08-03 | 2019-08-02 | H·李·莫菲特癌症中心与研究所公司 | Tlr9靶向治疗 |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
WO2019051355A1 (en) | 2017-09-08 | 2019-03-14 | Ohio State Innovation Foundation | NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS |
WO2020036862A1 (en) | 2018-08-13 | 2020-02-20 | Alnylam Pharmaceuticals, Inc. | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4104466A (en) * | 1974-03-13 | 1978-08-01 | Eishun Tsuchida | Polymeric metal complex and method of manufacturing the same |
IL69720A (en) * | 1983-09-14 | 1987-08-31 | Univ Ramot | Anti-tumor pharmaceutical compositions comprising liposome-bound porphyrins |
FR2567892B1 (fr) * | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
ATE68013T1 (de) * | 1985-07-05 | 1991-10-15 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
GB2213684A (en) * | 1987-12-11 | 1989-08-16 | Philips Electronic Associated | Data demodulator baud clock phase locking |
AU632993B2 (en) * | 1987-12-15 | 1993-01-21 | Gene Shears Pty. Limited | Ribozymes |
ATE152169T1 (de) * | 1988-02-05 | 1997-05-15 | Whitehead Biomedical Inst | Modifizierte hepatozyten und deren anwendung |
CA1339354C (en) * | 1988-09-01 | 1997-08-26 | The Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
US5225337A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
US5225347A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
WO1993001286A2 (en) * | 1991-06-28 | 1993-01-21 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
DK0638121T3 (da) * | 1992-04-28 | 1996-08-12 | Univ Yale | Målrettet spaltning af RNA under anvendelse af eukaryotisk ribonuklease P og ekstern ledersekvens |
JPH08507203A (ja) * | 1992-12-04 | 1996-08-06 | イノーバー ラボラトリーズ,インコーポレイテッド | 調節可能な核酸治療およびそれらの使用方法 |
DE69331911T2 (de) * | 1992-12-04 | 2002-11-21 | Ribozyme Pharmaceuticals, Inc. | Diagnose mittels signalverstärkung durch ein ribozym |
US6012375A (en) * | 1993-07-06 | 2000-01-11 | Eckstein; Donald B. | Aircraft infrared guided defense missile system |
AU706417B2 (en) * | 1994-02-23 | 1998-06-17 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting the expression of disease related genes |
US5869248A (en) * | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
AU4961996A (en) * | 1994-12-14 | 1996-07-03 | Innovir Laboratories, Inc. | Ribozyme-mediated inactivation of leukemia-associated rna |
-
1996
- 1996-03-14 US US08/615,961 patent/US5877162A/en not_active Expired - Lifetime
-
1997
- 1997-03-14 EP EP97915007A patent/EP0894129B1/de not_active Expired - Lifetime
- 1997-03-14 DK DK97915007T patent/DK0894129T3/da active
- 1997-03-14 JP JP53278697A patent/JP4062365B2/ja not_active Expired - Fee Related
- 1997-03-14 WO PCT/US1997/003847 patent/WO1997033991A1/en active IP Right Grant
- 1997-03-14 DE DE69729292T patent/DE69729292T2/de not_active Expired - Lifetime
- 1997-03-14 AU AU22061/97A patent/AU2206197A/en not_active Abandoned
- 1997-03-14 ES ES97915007T patent/ES2221955T3/es not_active Expired - Lifetime
- 1997-03-14 AT AT97915007T patent/ATE267866T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US5877162A (en) | 1999-03-02 |
DK0894129T3 (da) | 2004-09-27 |
EP0894129A1 (de) | 1999-02-03 |
JP2000506731A (ja) | 2000-06-06 |
ES2221955T3 (es) | 2005-01-16 |
DE69729292T2 (de) | 2005-06-02 |
EP0894129B1 (de) | 2004-05-26 |
WO1997033991A1 (en) | 1997-09-18 |
JP4062365B2 (ja) | 2008-03-19 |
ATE267866T1 (de) | 2004-06-15 |
AU2206197A (en) | 1997-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69729292D1 (de) | Kurze externe führungssequenzen | |
ATE465168T1 (de) | Xylo-lna analoge | |
CA2565103C (en) | Peptide conjugated, inosine-substituted antisense oligomer compound and method | |
DK0691980T3 (da) | 7-deazapurinmodifiderende oligonukleotider | |
WO2002036743A3 (en) | Antisense modulation of calreticulin expression | |
WO2003052072A3 (en) | Antisense modulation of estrogen receptor alpha expression | |
DK1123414T3 (da) | Antisense-modulering af integrin alpha 4.ekspression | |
DK1175489T3 (da) | Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider | |
EP1430072A4 (de) | Antisense-modulierung der expression des cholesterylestertransferproteins | |
WO2004016754A3 (en) | ANTISENSE MODULATION OF Nav1.3 EXPRESSION | |
DE69736276D1 (de) | Menschliche dnase resistent gegen actininhibitoren | |
EP1268507A4 (de) | Antisense-modulation der expression des transkriptionsfaktors e2f-1 | |
WO2003053341A3 (en) | Antisense modulation of ship-1 expression | |
EP1144690A4 (de) | Antisense modulation der expression des zellulären hemmstoffs der apoptose-2 | |
EP1163373A4 (de) | Antisense-modulation des zellulären hemmstoffs der apoptosis-expression | |
DE50110723D1 (de) | Isolierte luziferasen sowie deren verwendung | |
WO2003070878A3 (en) | Antisense modulation of hematopoietic cell protein tyrosine kinase expression | |
WO2003027229A3 (en) | Antisense modulation of rip2 expression | |
BR0313550A (pt) | modulação "antisense" da expressão de sintetase 1 de acil-coa | |
WO2003040161A3 (en) | Antisense modulation of activating transcription factor 3 expression | |
WO2003050247A3 (en) | Antisense modulation of mhc class ii transactivator expression | |
WO2003033659A3 (en) | Antisense modulation of matrix metalloproteinase 1 expression | |
WO2003106645A3 (en) | ANTISENSE MODULATION OF SMRT COREPRESSOR EXPRESSION | |
WO2003012033A3 (en) | Antisense modulation of short heterodimer partner-1 expression | |
EP1210454A4 (de) | Einflussnahme auf die shp-eprimierung durch antisense |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |